Recent Research Analysts’ Ratings Updates for FibroGen (FGEN)

FibroGen (NASDAQ: FGEN) has recently received a number of price target changes and ratings updates:

• 2/21/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/20/2025 – FibroGen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 2/13/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 2/5/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/1/2025 – FibroGen is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

FibroGen Price Performance

Shares of FibroGen stock opened at $0.71 on Monday. The firm has a market cap of $71.13 million, a price-to-earnings ratio of -0.57 and a beta of 0.75. The stock’s 50-day moving average is $0.53 and its 200-day moving average is $0.43. FibroGen, Inc. has a one year low of $0.18 and a one year high of $2.80.

Hedge Funds Weigh In On FibroGen

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of FibroGen in the fourth quarter valued at approximately $27,000. FMR LLC grew its position in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares in the last quarter. XTX Topco Ltd increased its stake in FibroGen by 423.8% during the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 77,693 shares during the period. Finally, Velan Capital Investment Management LP bought a new position in FibroGen during the 4th quarter worth $42,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.